CKD + Rectal (PR) Bleeding + Severe Anemia + Shortness of Breath

1. Understanding the Clinical Picture

2. Pathophysiology

Why CKD causes anemia

• The kidneys (peritubular fibroblasts in the renal cortex) produce erythropoietin (EPO) in response to hypoxia via HIF-2alpha transcription
• In CKD, these peritubular cells are destroyed or fibrosed - EPO production becomes driven by GFR level rather than hemoglobin level once eGFR <40 mL/min/1.73m²
• Anemia prevalence rises sharply below eGFR 30; severe anemia generally indicates CKD G4-G5
• Anemia is normocytic, normochromic in pure CKD, but becomes microcytic/hypochromic when iron deficiency coexists (as here, with PR bleeding)

Why CKD worsens bleeding

• Intrinsic platelet defects: Dysfunction of glycoprotein IIb/IIIa, abnormal expression of platelet glycoproteins, altered release of ADP and serotonin from alpha-granules, faulty arachidonic acid metabolism
• Extrinsic factors: Anemia itself worsens platelet adhesion - normally, red blood cells (RBCs) push platelets peripherally toward vessel walls (axial flow displacement), enabling contact with injured endothelium. In anemia, this displacement is lost and platelet adherence is impaired
• RBCs in CKD also release ADP and scavenge nitric oxide and PGI2, which are central regulators of platelet function
• Urea itself does NOT directly cause platelet dysfunction

3. Immediate Assessment - Key Questions

• CKD stage (eGFR, creatinine, on dialysis?)
• Nature of PR bleeding: fresh red blood vs. dark/maroon, amount, duration, associated symptoms (straining, mass, change in bowel habits, tenesmus)
• Severity of anemia: hemoglobin level, how fast it dropped
• Severity of SOB: exertional vs. rest, orthopnea (suggests fluid overload/cardiac)
• Medications: anticoagulants, antiplatelets (dangerous in CKD with platelet dysfunction), NSAIDs (cause GI bleeding AND worsen renal function)

• Hemodynamic instability (hypotension, tachycardia)
• Active brisk rectal bleeding
• Hb < 7 g/dL with symptoms
• Respiratory distress at rest

4. Investigations

For anemia workup:

For PR bleeding:

For shortness of breath:

5. Management

Step 1: Stabilize (A-B-C)

• O2 supplementation for SpO2 < 94%
• IV access, fluid resuscitation if hemodynamically compromised
• Cross-match blood if Hb < 7 or active bleeding

Step 2: Treat severe anemia - Blood Transfusion

• Target: Hb 9-10 g/dL (do not over-transfuse in CKD - risk of fluid overload, hyperkalemia from stored blood, transfusion reactions)
• In dialysis patients: transfuse during dialysis if possible to manage fluid and potassium
• Caution: Repeated transfusions cause iron overload and sensitization (creates HLA antibodies, complicating future transplantation). Use judiciously.

Step 3: Address uremic platelet dysfunction if active bleeding

• Desmopressin (DDAVP) 0.3 mcg/kg IV in 50 mL saline over 15-30 min: stimulates release of large vWF multimers from endothelial cells; improves bleeding time for 4-8 hours. Use for acute bleeding or pre-procedural cover. Note: tachyphylaxis occurs with repeated doses; do not use more than 2 doses
• Cryoprecipitate: contains vWF, factor VIII - improves bleeding time within 1 hour; effect lasts 24-36 hours
• Dialysis: Reduces uremic toxins contributing to platelet dysfunction; HD is first-line for uremic bleeding in dialysis-eligible patients
• Conjugated estrogens (0.6 mg/kg/day IV x 5 days or oral): onset 6 hours, effect lasts up to 2 weeks - for subacute/chronic bleeding management

Step 4: Long-term anemia management

• IV iron is preferred over oral iron in CKD, especially in:
  • Dialysis patients (IV iron mandatory)
  • Active GI bleeding (oral absorption impaired, GI irritation)
  • Inflammatory state (oral iron poorly absorbed)
• Available IV iron preparations:
  • Iron sucrose (most common, safest profile in CKD)
  • Ferric carboxymaltose (single large dose possible; note: risk of hypophosphatemia)
  • Ferumoxytol (equivalent to iron sucrose in CKD; alternative MRI contrast in CKD G4-5)
  • Low molecular weight iron dextran (test dose required)
• Target: ferritin 200-500 ng/mL (dialysis), 100-300 ng/mL (ND-CKD); TSAT 20-40%

• Epoetin alfa/beta or darbepoetin alfa once iron stores are replete
• KDIGO 2026: individualized approach; generally initiate when Hb < 10 g/dL, iron replete, no active infection/malignancy
• Target Hb: 10-11.5 g/dL (do NOT target >13 g/dL - increases risk of stroke, thrombosis per TREAT and CREATE trials)
• Caution with active GI bleeding: ESAs promote erythropoiesis but do nothing for active blood loss - treat the source first

• Roxadustat, daprodustat, molidustat, enarodustat
• Oral agents stimulating endogenous EPO production via HIF-2 pathway
• KDIGO 2026 suggests considering in ESA-hyporesponsive patients or where ESA unavailable
• Not first line in acute/severe bleeding scenarios

Step 5: Treat the source of rectal bleeding

• Hemorrhoids: rubber band ligation, sclerotherapy (preferred over surgery in CKD due to bleeding risk)
• Anal fissure: GTN cream, diltiazem topical, Botox injection
• Colorectal mass: Surgical/oncological referral (surgery risk must account for CKD)
• IBD: Mesalazine, steroids per GI team
• Avoid NSAIDs and anticoagulants unless absolutely required
• In uremic bleeding: treat with dialysis, DDAVP, or estrogens as above

6. Special Considerations

7. Summary Algorithm

CKD + PR Bleeding + Severe Anemia + SOB
       ↓
Is the patient hemodynamically unstable?
   YES → Resuscitate, pRBC transfusion, urgent gastroenterology review
   NO → Proceed with workup
       ↓
Characterize anemia:
  CBC, ferritin, TSAT, reticulocyte count, EPO
       ↓
Characterize bleeding source:
  Proctoscopy → Colonoscopy (once stable)
       ↓
Control active bleeding:
  DDAVP for uremic platelet dysfunction
  Treat local cause (banding, fissure Rx, etc.)
       ↓
Optimize iron stores:
  IV iron sucrose (preferred in CKD)
       ↓
Once iron replete + bleeding controlled:
  Start ESA (Epoetin/Darbepoetin)
  Target Hb 10-11.5 g/dL
       ↓
Long-term: CKD monitoring, nephrologist follow-up
           Consider dialysis planning if eGFR <15

• Brenner and Rector's The Kidney, pp. 2461-2485 (Anemia of Kidney Disease)
• Comprehensive Clinical Nephrology, 7th Ed, pp. 1171-1172 (Uremic Platelet Dysfunction & Treatment)
• KDIGO 2026 Anemia in CKD Guideline - most current international guideline (updated through October 2024 RCT data)
• UKKA 2024 Anaemia of CKD Guideline